Summary

Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months [FREEDOM; NCT00089791] was a randomized, placebo-controlled, Phase 3 trial designed to test the effect of denosumab on risk of fracture in postmenopausal women during a 3-year follow-up period [Cummings SR et al. N Engl J Med 2009].